Royalty Pharma (RPRX) Set to Announce Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) will release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Royalty Pharma to post earnings of $0.95 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.01. The firm had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter in the previous year, the company posted $0.85 EPS. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $27.20 on Tuesday. The company has a market cap of $16.14 billion, a P/E ratio of 24.07, a P/E/G ratio of 3.99 and a beta of 0.47. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The business’s 50 day moving average price is $27.95 and its 200-day moving average price is $27.56. Royalty Pharma has a fifty-two week low of $25.20 and a fifty-two week high of $31.66.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is presently 74.34%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Morgan Stanley upped their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday. The Goldman Sachs Group upped their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Citigroup cut their price objective on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.